All In MedTech

Device Trial Radar · NCT02097082

Treatment of SFA Lesions With 480 Biomedical STANZA™ Drug-Eluting Resorbable Scaffold (DRS) System

An Evaluation of the 480 Biomedical STANZA™ Drug-Eluting Resorbable Scaffold (DRS) System in the Treatment of de Novo SFA Lesions

Last checked: Nov 20, 2026Latest source record: Sep 6, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

28

Actual

Start

Oct 2013

Primary completion

Mar 30, 2016

Study completion May 2017

Sponsor

Lead sponsor
480 BiomedicalNot on our public-company list
Sponsor type
Industry
First posted
Mar 26, 2014

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

An evaluation of the safety and performance of the STANZA Drug-eluting Resorbable Scaffold (DRS) system for the treatment of patients with obstructive superficial femoral artery disease.

Conditions

  • Peripheral Arterial Disease
  • Intermittent Claudication
  • Vascular Diseases
  • Cardiovascular Diseases

Interventions

  • STANZA Drug-eluting resorbable ScaffoldDevice

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Patency by UltrasoundTime frame: through 6 months
  2. Major Adverse EventsTime frame: 30 days

Locations

9 sites in 4 countries. Site status is shown where the registry gives one.

  • Universitäts Klinikum Graz

    Graz, Austria

  • WGKK - Hanusch-Krankenhaus

    Vienna, Austria

  • Cardiovascular and Interventional Radiology- AKH

    Vienna, Austria

6 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.